Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Immunotherapy
Network
Solid tumors
Soluble profile
Toxicity
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
16
07
2022
accepted:
22
01
2023
medline:
15
6
2023
pubmed:
4
3
2023
entrez:
3
3
2023
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have particular, immune-related adverse events (irAEs), as a consequence of interfering with self-tolerance mechanisms. The incidence of irAEs varies depending on ICI class, administered dose and treatment schedule. The aim of this study was to define a baseline (T0) immune profile (IP) predictive of irAE development. A prospective, multicenter study evaluating the immune profile (IP) of 79 patients with advanced cancer and treated with anti-programmed cell death protein 1 (anti-PD-1) drugs as a first- or second-line setting was performed. The results were then correlated with irAEs onset. The IP was studied by means of multiplex assay, evaluating circulating concentration of 12 cytokines, 5 chemokines, 13 soluble immune checkpoints and 3 adhesion molecules. Indoleamine 2, 3-dioxygenase (IDO) activity was measured through a modified liquid chromatography-tandem mass spectrometry using the high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) method. A connectivity heatmap was obtained by calculating Spearman correlation coefficients. Two different networks of connectivity were constructed, based on the toxicity profile. Toxicity was predominantly of low/moderate grade. High-grade irAEs were relatively rare, while cumulative toxicity was high (35%). Positive and statistically significant correlations between the cumulative toxicity and IP10 and IL8, sLAG3, sPD-L2, sHVEM, sCD137, sCD27 and sICAM-1 serum concentration were found. Moreover, patients who experienced irAEs had a markedly different connectivity pattern, characterized by disruption of most of the paired connections between cytokines, chemokines and connections of sCD137, sCD27 and sCD28, while sPDL-2 pair-wise connectivity values seemed to be intensified. Network connectivity analysis identified a total of 187 statistically significant interactions in patients without toxicity and a total of 126 statistically significant interactions in patients with toxicity. Ninety-eight interactions were common to both networks, while 29 were specifically observed in patients who experienced toxicity. A particular, common pattern of immune dysregulation was defined in patients developing irAEs. This immune serological profile, if confirmed in a larger patient population, could lead to the design of a personalized therapeutic strategy in order to prevent, monitor and treat irAEs at an early stage.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICIs) have particular, immune-related adverse events (irAEs), as a consequence of interfering with self-tolerance mechanisms. The incidence of irAEs varies depending on ICI class, administered dose and treatment schedule. The aim of this study was to define a baseline (T0) immune profile (IP) predictive of irAE development.
METHODS
METHODS
A prospective, multicenter study evaluating the immune profile (IP) of 79 patients with advanced cancer and treated with anti-programmed cell death protein 1 (anti-PD-1) drugs as a first- or second-line setting was performed. The results were then correlated with irAEs onset. The IP was studied by means of multiplex assay, evaluating circulating concentration of 12 cytokines, 5 chemokines, 13 soluble immune checkpoints and 3 adhesion molecules. Indoleamine 2, 3-dioxygenase (IDO) activity was measured through a modified liquid chromatography-tandem mass spectrometry using the high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) method. A connectivity heatmap was obtained by calculating Spearman correlation coefficients. Two different networks of connectivity were constructed, based on the toxicity profile.
RESULTS
RESULTS
Toxicity was predominantly of low/moderate grade. High-grade irAEs were relatively rare, while cumulative toxicity was high (35%). Positive and statistically significant correlations between the cumulative toxicity and IP10 and IL8, sLAG3, sPD-L2, sHVEM, sCD137, sCD27 and sICAM-1 serum concentration were found. Moreover, patients who experienced irAEs had a markedly different connectivity pattern, characterized by disruption of most of the paired connections between cytokines, chemokines and connections of sCD137, sCD27 and sCD28, while sPDL-2 pair-wise connectivity values seemed to be intensified. Network connectivity analysis identified a total of 187 statistically significant interactions in patients without toxicity and a total of 126 statistically significant interactions in patients with toxicity. Ninety-eight interactions were common to both networks, while 29 were specifically observed in patients who experienced toxicity.
CONCLUSIONS
CONCLUSIONS
A particular, common pattern of immune dysregulation was defined in patients developing irAEs. This immune serological profile, if confirmed in a larger patient population, could lead to the design of a personalized therapeutic strategy in order to prevent, monitor and treat irAEs at an early stage.
Identifiants
pubmed: 36869232
doi: 10.1007/s00262-023-03384-9
pii: 10.1007/s00262-023-03384-9
pmc: PMC10264536
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Cytokines
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2217-2231Informations de copyright
© 2023. The Author(s).
Références
Nat Rev Genet. 2011 Jan;12(1):56-68
pubmed: 21164525
Immune Netw. 2020 Feb 17;20(1):e9
pubmed: 32158597
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Chest. 2002 Dec;122(6 Suppl):298S-301S
pubmed: 12475804
J Hypertens. 2021 Jul 1;39(7):1274-1281
pubmed: 34074965
J Pers Med. 2021 Jul 10;11(7):
pubmed: 34357118
Acta Pharm Sin B. 2021 Apr;11(4):941-960
pubmed: 33996408
Int J Mol Sci. 2020 Dec 22;22(1):
pubmed: 33375194
Wiley Interdiscip Rev Syst Biol Med. 2020 Nov;12(6):e1489
pubmed: 32307915
Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2147-52
pubmed: 16825597
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Allergol Int. 2022 Apr;71(2):169-178
pubmed: 35101349
Front Immunol. 2021 Jul 22;12:670391
pubmed: 34367136
Chest. 2018 Dec;154(6):1416-1423
pubmed: 30189190
J Clin Endocrinol Metab. 2004 Nov;89(11):5496-9
pubmed: 15531503
Br J Cancer. 2017 Jan;116(3):310-317
pubmed: 28072766
Curr Med Chem. 2020;27(8):1350-1366
pubmed: 31272342
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11695-700
pubmed: 16864790
Hum Vaccin Immunother. 2022 May 31;18(3):2034377
pubmed: 35258435
J Immunol. 1999 Nov 15;163(10):5686-92
pubmed: 10553099
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Eur J Intern Med. 2021 Nov;93:87-94
pubmed: 34391591
Acta Oncol. 2021 Dec;60(12):1597-1603
pubmed: 34549686
J Transl Med. 2021 Mar 23;19(1):119
pubmed: 33757546
Rheumatology (Oxford). 2022 Feb 2;61(2):815-825
pubmed: 33930105
Expert Opin Investig Drugs. 2021 May;30(5):555-569
pubmed: 33650931
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Nat Immunol. 2018 Mar;19(3):302-314
pubmed: 29476184
Br J Surg. 2006 Oct;93(10):1226-31
pubmed: 16838393
Eur Cytokine Netw. 2004 Apr-Jun;15(2):91-8
pubmed: 15319166
Mediators Inflamm. 2005 Oct 24;2005(5):273-9
pubmed: 16258194
Eur Respir J. 2017 Aug 10;50(2):
pubmed: 28798088
Nat Rev Clin Oncol. 2022 Apr;19(4):237-253
pubmed: 34997230
Autoimmunity. 2004 Aug;37(5):273-82
pubmed: 15672495
J Exp Med. 2014 May 5;211(5):943-59
pubmed: 24752301
Cancer Immunol Immunother. 2019 Jan;68(1):97-107
pubmed: 30311027
Immunol Med. 2020 Mar;43(1):1-9
pubmed: 31822213
Front Immunol. 2020 Jan 14;10:3056
pubmed: 31993059
Cell. 2021 Oct 14;184(21):5309-5337
pubmed: 34624224
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Eur J Cancer. 2021 Jan;142:18-28
pubmed: 33212418
Inflammopharmacology. 2022 Apr;30(2):435-451
pubmed: 35188599
Arthritis Care Res (Hoboken). 2021 Feb;73(2):180-187
pubmed: 31785183
Adv Pharmacol. 2021;91:111-139
pubmed: 34099106
Br J Clin Pharmacol. 2020 Sep;86(9):1690-1702
pubmed: 32323342
J Clin Oncol. 2021 Dec 20;39(36):4073-4126
pubmed: 34724392
Trends Immunol. 2021 Apr;42(4):293-311
pubmed: 33714688
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Thorax. 2000 Dec;55(12):1023-7
pubmed: 11083887
J Exp Med. 1995 Jul 1;182(1):219-31
pubmed: 7790818
Nat Rev Clin Oncol. 2022 Jan;19(1):37-50
pubmed: 34580473
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Front Immunol. 2022 Nov 03;13:974087
pubmed: 36405727
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E488-E497
pubmed: 29282317
Curr Oncol Rep. 2020 Mar 21;22(4):39
pubmed: 32200442
J Pers Med. 2020 Nov 04;10(4):
pubmed: 33158018
Front Immunol. 2021 May 03;12:669474
pubmed: 34012451
Nat Rev Rheumatol. 2021 Apr;17(4):213-223
pubmed: 33686279
J Clin Pathol. 1992 Oct;45(10):880-4
pubmed: 1430258
Arch Neurol. 2001 Dec;58(12):1975-80
pubmed: 11735771
Cancers (Basel). 2020 Sep 14;12(9):
pubmed: 32937860
Asia Pac J Oncol Nurs. 2017 Apr-Jun;4(2):127-135
pubmed: 28503645
J Periodontol. 1993 May;64(5 Suppl):456-60
pubmed: 8315568
Cancer. 2021 May 1;127(9):1360-1368
pubmed: 33662145
Thorac Cancer. 2020 Apr;11(4):835-839
pubmed: 32043828
FEBS Lett. 1992 Jul 27;307(1):97-101
pubmed: 1639201
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Med Res Rev. 2021 Jan;41(1):156-201
pubmed: 32844499
Front Immunol. 2021 Aug 09;12:705096
pubmed: 34434192
N Engl J Med. 2021 Aug 19;385(8):683-694
pubmed: 34407342
J Immunother Cancer. 2019 Dec 17;7(1):353
pubmed: 31847881
Nat Rev Drug Discov. 2022 Jul;21(7):495-508
pubmed: 34316029
Eur J Endocrinol. 2005 Feb;152(2):171-7
pubmed: 15745922
Am J Pathol. 2002 Jul;161(1):195-206
pubmed: 12107104
Am J Epidemiol. 2016 Mar 1;183(5):403-6
pubmed: 26888748
NPJ Syst Biol Appl. 2021 Jan 21;7(1):3
pubmed: 33479222
J Clin Oncol. 2021 Feb 20;39(6):599-607
pubmed: 33125309
Nutr Metab Cardiovasc Dis. 2011 Oct;21(10):817-22
pubmed: 20685094
Pharmacol Rep. 2009 Jan-Feb;61(1):22-32
pubmed: 19307690
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):194-9
pubmed: 16239601
J Immunol. 1997 Aug 1;159(3):1437-43
pubmed: 9233641
Front Immunol. 2019 Mar 06;10:379
pubmed: 30894861